Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Description of Covariates
2.3. Statistical Analysis
3. Results
3.1. Demographics
3.2. Outcomes following PN versus RN
3.3. Impact of Surgical Approach
3.4. Predictors of Perioperative Events
3.4.1. Infectious
3.4.2. Cardiovascular
3.4.3. VTE
3.4.4. Bleeding
3.4.5. Renal
3.4.6. Urine and Lymph Leak
3.4.7. Readmissions and Reoperations
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kunath, F.; Schmidt, S.; Krabbe, L.-M.; Miernik, A.; Dahm, P.; Cleves, A.; Walther, M.; Kroeger, N. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst. Rev. 2017, 2017, CD012045. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017, 67, 7–30. [Google Scholar] [CrossRef] [Green Version]
- Padala, S.A.; Barsouk, A.; Thandra, K.C.; Saginala, K.; Mohammed, A.; Vakiti, A.; Rawla, P.; Barsouk, A. Epidemiology of Renal Cell Carcinoma. World J. Oncol. 2020, 11, 79–87. [Google Scholar] [CrossRef] [PubMed]
- Chandrasekar, T.; Klaassen, Z.; Goldberg, H.; Kulkarni, G.S.; Hamilton, R.J.; Fleshner, N.E. Metastatic renal cell carcinoma: Patterns and predictors of metastases—A contemporary population-based series. Urol. Oncol. Semin. Orig. Investig. 2017, 35, 661.e7–661.e14. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.-J.; Leppert, J.T.; Maxwell, B.G.; Panousis, P.; Chung, B.I. Trends and perioperative outcomes for laparoscopic and robotic nephrectomy using the National Surgical Quality Improvement Program (NSQIP) database. Urol. Oncol. Semin. Orig. Investig. 2014, 32, 473–479. [Google Scholar] [CrossRef]
- Alanee, S.; Nutt, M.; Moore, A.; Holland, B.; Dynda, D.; Wilber, A.; El-Zawahry, A. Partial nephrectomy for T2 renal masses: Contemporary trends and oncologic efficacy. Int. Urol. Nephrol. 2015, 47, 945–950. [Google Scholar] [CrossRef] [PubMed]
- Long, C.J.; Canter, D.J.; Kutikov, A.; Li, T.; Simhan, J.; Smaldone, M.C.; Teper, E.; Viterbo, R.; Boorjian, S.A.; Chen, D.Y.; et al. Partial nephrectomy for renal masses ≥ 7 cm: Technical, oncological and functional outcomes. Br. J. Urol. 2012, 109, 1450–1456. [Google Scholar] [CrossRef] [PubMed]
- Huang, R.; Zhang, C.; Wang, X.; Hu, H. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T2 or Higher Stage Renal Tumors: A Systematic Review and Meta-Analysis. Front. Oncol. 2021, 11, 680842. [Google Scholar] [CrossRef]
- Mir, M.C.; Derweesh, I.; Porpiglia, F.; Zargar, H.; Mottrie, A.; Autorino, R. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur. Urol. 2016, 71, 606–617. [Google Scholar] [CrossRef]
- Vilaseca, A.; Guglielmetti, G.; Vertosick, E.A.; Sjoberg, D.D.; Grasso, A.; Benfante, N.E.; Nguyen, D.P.; Corradi, R.B.; Coleman, J.; Russo, P.; et al. Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. Eur. Urol. Oncol. 2020, 3, 365–371. [Google Scholar] [CrossRef]
- Klett, D.E.; Tsivian, M.; Packiam, V.T.; Lohse, C.M.; Ahmed, M.E.; A Potretzke, T.; Gopalakrishna, A.; Boorjian, S.A.; Thompson, R.H.; Leibovich, B.C.; et al. Partial versus radical nephrectomy in clinical T2 renal masses. Int. J. Urol. 2021, 28, 1149–1154. [Google Scholar] [CrossRef]
- Scosyrev, E.; Messing, E.M.; Sylvester, R.; Campbell, S.; Van Poppel, H. Renal Function after Nephron-sparing Surgery Versus Radical Nephrectomy: Results from EORTC Randomized Trial 30904. Eur. Urol. 2014, 65, 372–377. [Google Scholar] [CrossRef] [PubMed]
- Veccia, A.; Dell’Oglio, P.; Antonelli, A.; Minervini, A.; Simone, G.; Challacombe, B.; Perdonà, S.; Porter, J.; Zhang, C.; Capitanio, U.; et al. Robotic partial nephrectomy versus radical nephrectomy in elderly patients with large renal masses. Minerva Urol. Nefrol. 2020, 72, 99–108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Poppel, H.; Da Pozzo, L.; Albrecht, W.; Matveev, V.; Bono, A.; Borkowski, A.; Marechal, J.-M.; Klotz, L.; Skinner, E.; Keane, T.; et al. A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. Eur. Urol. 2007, 51, 1606–1615. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chandrasekar, T.; Boorjian, S.A.; Capitanio, U.; Gershman, B.; Mir, M.C.; Kutikov, A. Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. Eur. Urol. 2021, 80, 575–588. [Google Scholar] [CrossRef]
- Streja, E.; Kalantar-Zadeh, K.; Molnar, M.Z.; Landman, J.; Arah, O.A.; Kovesdy, C.P. Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans. Nephrol. Dial. Transplant. 2016, 33, 95–101. [Google Scholar] [CrossRef] [Green Version]
- Network NCC. Kidney Cancer. National Comprehensive Cancer Network Guidelines for Patients; National Comprehensive Cancer Network, Inc.: Plymouth Meeting, PA, USA, 2022; Available online: https://www.nccn.org/patients/guidelines/content/PDF/kidney-patient.pdf (accessed on 8 July 2022).
- Bamias, A.; Escudier, B.; Sternberg, C.N.; Zagouri, F.; Dellis, A.; Djavan, B.; Tzannis, K.; Kontovinis, L.; Stravodimos, K.; Papatsoris, A.; et al. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist 2017, 22, 667–679. [Google Scholar] [CrossRef] [Green Version]
- Aubert, N.D.S.; Audenet, F.; Mccaig, F.; Delavaud, C.; Verkarre, V.; Le Guilchet, T.; Dariane, C.; Pettenati, C.; Slaoui, H.; Mejean, A.; et al. Nephron sparing surgery in tumours greater than 7 cm. Prog. Urol. 2018, 28, 336–343. [Google Scholar] [CrossRef]
- Mahran, A.; Mishra, K.; Omil-Lima, D.; Abboud, B.; Wang, M.; Jankowski, J.; Abouassaly, R.; Ponsky, L.; Lengu, I.; Bukavina, L. Is there a benefit to additional neuroaxial anesthesia in open nephrectomy? A prospective NSQIP propensity score analysis. Int. Urol. Nephrol. 2019, 51, 1481–1489. [Google Scholar] [CrossRef]
- Venkatramani, V.; Koru-Sengul, T.; Miao, F.; Nahar, B.; Prakash, N.S.; Swain, S.; Punnen, S.; Ritch, C.; Gonzalgo, M.; Parekh, D. A comparison of overall survival and perioperative outcomes between partial and radical nephrectomy for cT1b and cT2 renal cell carcinoma—Analysis of a national cancer registry. Urol. Oncol. Semin. Orig. Investig. 2018, 36, 90.e9–90.e14. [Google Scholar] [CrossRef]
- Leow, J.J.; Gandaglia, G.; Sood, A.; Ruhotina, N.; E Klett, D.; Sammon, J.D.; Schmid, M.; Sun, M.; Chang, S.L.; Kibel, A.S.; et al. Readmissions after major urologic cancer surgery. Can. J. Urol. 2014, 21, 7537–7546. [Google Scholar] [PubMed]
- Pereira, J.; Renzulli, J.; Pareek, G.; Moreira, D.; Guo, R.; Zhang, Z.; Amin, A.; Mega, A.; Golijanin, D.; Gershman, B. Perioperative Morbidity of Open Versus Minimally Invasive Partial Nephrectomy: A Contemporary Analysis of the National Surgical Quality Improvement Program. J. Endourol. 2018, 32, 116–123. [Google Scholar] [CrossRef]
- Suek, T.; Davaro, F.; Raza, S.J.; Hamilton, Z. Robotic surgery for cT2 kidney cancer: Analysis of the National Cancer Database. J. Robot. Surg. 2021, 16, 723–729. [Google Scholar] [CrossRef] [PubMed]
- Palacios, D.A.; Li, J.; Mahmood, F.; Demirjian, S.; Abouassaly, R.; Campbell, S.C. Partial Nephrectomy for Patients with Severe Chronic Kidney Disease—Is It Worthwhile? J. Urol. 2020, 204, 434–441. [Google Scholar] [CrossRef] [PubMed]
- Flammia, R.S.; Anceschi, U.; Tufano, A.; Tuderti, G.; Ferriero, M.C.; Brassetti, A.; Mari, A.; Di Maida, F.; Minervini, A.; Derweesh, I.H.; et al. Is Hypertension Associated with Worse Renal Functional Outcomes after Minimally Invasive Partial Nephrectomy? Results from a Multi-Institutional Cohort. J. Clin. Med. 2022, 11, 1243. [Google Scholar] [CrossRef]
- Nasrallah, A.A.; Dakik, H.A.; Heidar, N.F.A.; Najdi, J.A.; Nasrallah, O.G.; Mansour, M.; Tamim, H.; El Hajj, A. Major adverse cardiovascular events following partial nephrectomy: A procedure-specific risk index. Ther. Adv. Urol. 2022, 14, 17562872221084847. [Google Scholar] [CrossRef]
- Garden, E.B.; Ravivarapu, K.T.; Levy, M.; Chin, C.P.; Omidele, O.; Tomer, N.; Al-Alao, O.; Araya, J.S.; Small, A.C.; Palese, M.A. The Utilization and Safety of Same-Day Discharge After Transurethral Benign Prostatic Hyperplasia Surgery: A Case-Control, Matched Analysis of a National Cohort. Urology 2022, 165, 59–66. [Google Scholar] [CrossRef]
- Fuchshuber, P.R.; Greif, W.; Tidwell, C.R.; Klemm, M.S.; Frydel, C.; Wali, A.; Rosas, E.; Clopp, M.P. The Power of the National Surgical Quality Improvement Program—Achieving A Zero Pneumonia Rate in General Surgery Patients. Perm. J. 2012, 16, 39–45. [Google Scholar] [CrossRef] [Green Version]
- Kutikov, A.; Uzzo, R.G. The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth. J. Urol. 2009, 182, 844–853. [Google Scholar] [CrossRef]
- Canter, D.; Kutikov, A.; Manley, B.; Egleston, B.; Simhan, J.; Smaldone, M.; Teper, E.; Viterbo, R.; Chen, D.Y.; Greenberg, R.E.; et al. Utility of the R.E.N.A.L. Nephrometry Scoring System in Objectifying Treatment Decision-making of the Enhancing Renal Mass. Urology 2011, 78, 1089–1094. [Google Scholar] [CrossRef]
Baseline Characteristics | All Patients n = 2094 | Partial Nephrectomy n = 816 (38.97%) | Radical Nephrectomy n = 1278 (61.03%) | p-Value | |
---|---|---|---|---|---|
Age | Mean, SD (years) | 61.50, 12.40 | 60.22, 12.25 | 62.32, 12.42 | <0.001 |
Sex | Female n, % | 722 | 260 (36.01%) | 462 (63.99%) | 0.044 |
Male n, % | 1372 | 556 (40.52%) | 816 (59.48%) | ||
Ethnicity | Hispanic | 121 | 44 (36.36%) | 77 (63.64%) | 0.370 |
Not Hispanic | 1632 | 649 (39.77%) | 983 (60.23%) | ||
Unknown | 341 | 123 (36.07%) | 218 (63.93%) | ||
Race | White | 1375 | 528 (38.4%) | 847 (61.6%) | 0.029 |
Asian/ Pacific Islander | 64 | 26 (40.63%) | 38 (59.38%) | ||
Black | 222 | 105 (47.3%) | 117 (52.7%) | ||
American Indian/ Alaskan | 21 | 4 (19.05%) | 17 (80.95%) | ||
Unknown | 412 | 153 (37.14%) | 259 (62.86%) | ||
RCC Stage | T1b | 1516 | 730 (48.15%) | 786 (51.85%) | <0.001 |
T2a | 351 | 56 (15.95%) | 295 (84.05%) | ||
T2b | 178 | 22 (12.36%) | 156 (87.64%) | ||
T2, unspecified | 49 | 8 (16.33%) | 41 (83.67%) | ||
Functional Status | Independent | 2068 | 809 (39.12%) | 1259 (60.88%) | 0.834 |
Partially Dependent | 23 | 7 (30.43%) | 16 (69.57%) | ||
Totally Dependent | 2 | 0 (0.00%) | 2 (100.00%) | ||
Unknown | 1 | 0 (0.00%) | 1 (100.00%) | ||
Intraabdominal Drain Placement | 676 | 544 (80.47%) | 132 (19.53%) | <0.001 | |
Peri-operative Antibiotic Use | <24 h | 1897 | 755 (39.8%) | 1142 (60.2%) | 0.097 |
24–72 h | 147 | 47 (31.97%) | 100 (68.03%) | ||
>72 h | 33 | 10 (30.3%) | 23 (69.7%) | ||
None | 17 | 4 (23.53%) | 13 (76.47%) | ||
VTE Prophylaxis Method | Mechanical | 625 | 297 (47.52%) | 328 (52.48%) | <0.001 |
Pharmacologic | 121 | 33 (27.27%) | 88 (72.73%) | ||
Mechanical and Pharmacologic | 1293 | 463 (35.81%) | 830 (64.19%) | ||
None | 55 | 23 (41.82%) | 32 (58.18%) | ||
Surgical Approach | Open | 519 | 252 (48.55%) | 267 (51.45%) | <0.001 |
Laparoscopic | 495 | 66 (13.33%) | 429 (86.67%) | ||
Robotic | 683 | 384 (56.22%) | 299 (43.78%) | ||
Hybrid, Open Assist/ Conversion | 397 | 114 (28.72%) | 283 (71.28%) | ||
Surgical Measures | Mean LOS, SD (days) | 3.08, 2.80 | 3.13, 2.86 | 3.04, 2.88 | 0.472 |
Mean Operative Time, SD (minutes) | 172.08, 75.7 | 198.45, 72.81 | 155.24, 72.75 | <0.001 | |
Readmissions | 117 | 57 (48.72%) | 60 (51.28%) | 0.026 | |
Reoperations | 37 | 17 (45.95%) | 20 (54.05%) | 0.380 |
Peri-Operative Characteristics | All Patients n = 2094 | Partial Nephrectomy n = 816 | Radical Nephrectomy n = 1278 | p-Value | |
---|---|---|---|---|---|
Medical History | Diabetes | 478 (22.83%) | 215 (26.35%) | 263 (20.58%) | 0.002 |
Smoking | 385 (18.39%) | 149 (18.26%) | 236 (18.47%) | 0.905 | |
Dyspnea | 143 (6.83%) | 56 (6.86%) | 87 (6.81%) | 0.961 | |
Chronic Obstructive Pulmonary Disease | 84 (4.01%) | 25 (3.06%) | 59 (4.62%) | 0.077 | |
Chronic Heart Failure | 15 (0.72%) | 4 (0.49%) | 11 (0.86%) | 0.961 | |
Hypertension | 1334 (63.71%) | 518 (63.48%) | 816 (63.85%) | 0.864 | |
Pre-operative (≤24 h) Acute Renal Failure | 4 (0.19%) | 2 (0.25%) | 2 (0.16%) | 0.651 | |
Dialysis | 32 (1.53%) | 2 (0.25%) | 30 (2.35%) | <0.001 | |
Disseminated Cancer | 49 (2.34%) | 14 (1.72%) | 35 (2.74%) | 0.131 | |
Chronic Steroid Use | 67 (3.2%) | 25 (3.06%) | 42 (3.29%) | 0.778 | |
Bleeding Disorder | 60 (2.87%) | 20 (2.45%) | 40 (3.13%) | 0.364 | |
Mean Pre-operative Creatinine, SD | 10.72, 27.70 | 10.65, 29.63 | 10.76, 26.41 | 0.093 | |
Peri-operative Complications | Surgical Site Infections | 40 (1.91%) | 14 (1.71%) | 26 (2.03%) | 0.744 |
Superficial Infection | 37 (1.77%) | 13 (1.59%) | 24 (1.88%) | 0.630 | |
Deep Wound Infection | 3 (0.14%) | 1 (0.12%) | 2 (0.16%) | 0.841 | |
Organ/Space Infection | 19 (0.91%) | 9 (1.1%) | 10 (0.78%) | 0.451 | |
Wound Dehiscence | 5 (0.24%) | 1 (0.12%) | 4 (0.31%) | 0.383 | |
Pneumonia | 37 (1.77%) | 16 (1.96%) | 21 (1.64%) | 0.591 | |
Reintubation | 13 (0.62%) | 7 (0.86%) | 6 (0.47%) | 0.270 | |
VTE | 26 (1.24%) | 13 (1.16%) | 13 (1.02%) | 0.312 | |
Deep Vein Thrombosis | 14 (0.67%) | 8 (0.98%) | 6 (0.47%) | 0.162 | |
Pulmonary Embolism | 18 (0.86%) | 10 (1.23%) | 8 (0.63%) | 0.147 | |
Ventilation > 72 h | 9 (0.43%) | 6 (0.74%) | 3 (0.23%) | 0.088 | |
Acute Kidney Injury | 14 (0.67%) | 9 (1.1%) | 5 (0.39%) | 0.051 | |
Renal Failure Requiring Dialysis | 14 (0.67%) | 10 (1.23%) | 4 (0.31%) | 0.013 | |
Urinary Tract Infection | 28 (1.34%) | 13 (1.59%) | 15 (1.17%) | 0.415 | |
Cardiovascular Events | 20 (0.96%) | 5 (0.61%) | 15 (1.17%) | 0.252 | |
Cerebrovascular Accident | 2 (0.10%) | 0 (0.00%) | 2 (0.16%) | 0.84 | |
Cardiac Arrest | 6 (0.29%) | 2 (0.25%) | 4 (0.31%) | 0.777 | |
Myocardial Infarction | 12 (0.57%) | 3 (0.37%) | 9 (0.7%) | 0.320 | |
Sepsis Events | 20 (0.96%) | 8 (0.98%) | 12 (0.94%) | >0.999 | |
Sepsis | 16 (0.76%) | 6 (0.74%) | 10 (0.78%) | 0.904 | |
Septic Shock | 4 (0.19%) | 2 (0.25%) | 2 (0.16%) | 0.651 | |
Bleeding Req. Transfusion ≤ 72 h | 146 (6.97%) | 75 (9.19%) | 71 (5.56%) | 0.001 | |
Urine Leak or Ureteric Fistula | 13 (0.62%) | 9 (1.10%) | 4 (0.31%) | 0.025 | |
Ureteral Obstruction | 7 (0.33%) | 5 (0.61%) | 2 (0.16%) | 0.572 | |
Lymphocele or Lymphatic Leak | 36 (1.72%) | 17 (2.08%) | 19 (1.49%) | 0.306 |
Complication | Comorbidity (Ref: No Comorbidity) | OR | 95% CI | p-Value |
---|---|---|---|---|
Wound Dehiscence | Renal failure | 175.494 | 12.591–2446.070 | <0.001 |
Pneumonia | COPD | 5.789 | 2.229–15.035 | <0.001 |
Bleeding Disorder | 6.596 | 2.413–18.033 | <0.001 | |
Reintubation | Bleeding Disorder | 5.523 | 1.089–28.010 | 0.039 |
VTE | Open (Ref: Minimally Invasive) | 2.480 | 1.121–5.484 | 0.025 |
Chronic steroid use | 4.245 | 1.213–14.847 | 0.024 | |
Deep Vein Thrombosis | Open (Ref: Minimally Invasive) | 3.959 | 1.325–11.829 | 0.014 |
Chronic steroid use | 10.048 | 2.616–38.595 | <0.001 | |
Pulmonary Embolism | COPD | 5.212 | 1.269–21.411 | 0.022 |
Acute Kidney Injury | Hypertension | 7.689 | 1.008–61.406 | 0.049 |
Renal Failure Requiring Dialysis | Renal failure | 45.734 | 2.838–736.989 | 0.007 |
Open (Ref: Minimally Invasive) | 5.859 | 1.783–19.252 | 0.004 | |
Urinary Tract Infection | Hypertension | 3.012 | 1.013–8.954 | 0.047 |
Myocardial Infarction | Diabetes | 4.988 | 1.412–17.616 | 0.013 |
Bleeding Req. Transfusion ≤ 72 h | PN (Ref: RN) | 1.524 | 1.061–2.188 | 0.023 |
Open (Ref: Minimally Invasive) | 5.070 | 3.540–7.261 | <0.001 | |
Dialysis | 3.825 | 1.547–9.458 | 0.004 | |
Bleeding disorder | 3.105 | 1.502–6.418 | 0.002 | |
Lymphocele or Lymphatic Leak | Renal failure | 12.369 | 1.117–136.937 | 0.040 |
Dialysis | 6.680 | 1.751–25.487 | 0.005 | |
30-day Readmissions | PN (Ref: RN) | 1.568 | 1.062–2.315 | 0.024 |
Open (Ref: Minimally Invasive) | 1.611 | 1.080–2.402 | 0.019 | |
Renal failure | 12.734 | 1.575–102.945 | 0.017 | |
Chronic steroid use | 2.511 | 1.153–5.471 | 0.020 | |
COPD | 2.646 | 1.256–5.575 | 0.010 | |
30-day Reoperations | Renal failure | 40.017 | 4.580–349.666 | <0.001 |
Chronic steroid use | 4.066 | 1.364–12.125 | 0.012 | |
Bleeding disorder | 4.256 | 1.424–12.722 | 0.010 |
Peri-Operative Complications | Associated Comorbidities | Comorbid vs. Non-Comorbid Patients Experiencing Complication | p-Value |
---|---|---|---|
Wound Dehiscence | Pre-operative renal failure | 25.0% vs. 0.19% | 0.010 |
Pneumonia | COPD | 8.3% vs. 1.5% | <0.001 |
Bleeding disorder | 8.3% vs. 1.6% | 0.004 | |
Ventilation > 72 h | Bleeding disorder | 3.3% vs. 0.3% | 0.026 |
Acute Kidney Injury | Hypertension | 1.0% vs. 0.1% | 0.024 |
Renal Failure Requiring Dialysis | Pre-operative acute renal failure | 25.0% vs. 0.6% | 0.027 |
Urinary Tract Infection | Diabetes | 2.3% vs. 1.1% | 0.043 |
Hypertension | 1.8% vs. 0.5% | 0.016 | |
Bleeding Transfusion | Diabetes | 10.5% vs. 5.9% | 0.001 |
Hypertension | 8.2% vs. 4.9% | 0.004 | |
Dialysis | 25.0% vs. 6.7% | 0.001 | |
Bleeding disorder | 18.3% vs. 6.6% | 0.002 | |
Urine Leak or Ureteric Fistula | Hypertension | 0.9% vs. 0.1% | 0.040 |
Lymphocele or Lymphatic Leak | Dialysis | 8.3% vs. 1.4% | 0.016 |
30-day Readmissions | COPD | 11.9% vs. 5.3% | 0.024 |
Pre-operative acute renal failure | 50.0% vs. 5.5% | 0.017 | |
Dialysis | 15.6% vs. 5.4% | 0.030 | |
Bleeding disorder | 11.7% vs. 5.4% | 0.047 | |
30-day Reoperations | Pre-operative acute renal failure | 50.0% vs. 1.7% | 0.002 |
Dialysis | 9.4% vs. 1.7% | 0.018 | |
Chronic steroid use | 6.0% vs. 1.6% | 0.029 | |
Bleeding disorder | 6.7% vs. 1.6% | 0.020 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shah, Y.B.; Simhal, R.K.; Wang, K.R.; Goldberg, H.; Lallas, C.D.; Chandrasekar, T. Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy. J. Clin. Med. 2023, 12, 175. https://doi.org/10.3390/jcm12010175
Shah YB, Simhal RK, Wang KR, Goldberg H, Lallas CD, Chandrasekar T. Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy. Journal of Clinical Medicine. 2023; 12(1):175. https://doi.org/10.3390/jcm12010175
Chicago/Turabian StyleShah, Yash B., Rishabh K. Simhal, Kerith R. Wang, Hanan Goldberg, Costas D. Lallas, and Thenappan Chandrasekar. 2023. "Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy" Journal of Clinical Medicine 12, no. 1: 175. https://doi.org/10.3390/jcm12010175
APA StyleShah, Y. B., Simhal, R. K., Wang, K. R., Goldberg, H., Lallas, C. D., & Chandrasekar, T. (2023). Patient Factors Impacting Perioperative Outcomes for T1b-T2 Localized Renal Cell Carcinoma May Guide Decision for Partial versus Radical Nephrectomy. Journal of Clinical Medicine, 12(1), 175. https://doi.org/10.3390/jcm12010175